ISAL 2023 | The incidence of fungal disease in patients with FLT3-mutated AML treated with midostaurin
Livio Pagano, MD, Catholic University of Sacred Heart, Rome, Italy, discusses a study which evaluated the incidence of fungal infection in patients with FLT3-mutated acute myeloid leukemia (AML) treated with midostaurin, and further aimed to determine whether antifungal prophylaxis could be avoided. This study demonstrated that prophylaxis is mandatory in this patient population, and Prof. Pagano further highlights the need to find the best method of administering both midostaurin and prophylactic agents to improve patient outcomes and avoid toxic drug-drug interactions. This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Board member of Gilead Science, MSD, Pfizer, Stemline, Basilea, Janssen-Cilab, Novartis, Jazz Pharmaceutical, Cidara and has been speaker for Gilead Sciences, Kiowa Kirin, MSD, Pfizer Pharmaceuticals, Astellas Pharma, Novartis, Jazz Pharmaceutical. Consultant for Menarini
